| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9253737 | Journal of Hepatology | 2005 | 7 Pages |
Abstract
Treatment with pegylated interferon α-2b plus ribavirin in the acute phase of HCV reinfection yielded an EVR of 62.5% and a SVR of 34.7%. The combination was safe, with a low rate of therapy withdrawal.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
LluÃs Castells, VÃctor Vargas, Helena Allende, Itxarone Bilbao, José Luis Lázaro, Carlos Margarit, Rafael Esteban, Jaime Guardia,